ProCE Banner Activity

Mechanisms of Action of EZH1 and EZH2 and Anti-EZH1 and EZH2 Therapies

Slideset Download
Download these slides from a live expert-led satellite symposium reviewing the mechanisms of Anti-EZH1 and EZH2 therapies in PTCL.

Released: June 02, 2022

Expiration: June 01, 2023

No longer available for credit.

Share

Faculty

Steven M. Horwitz

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Pierluigi Porcu

Pierluigi Porcu, MD

Professor and Director
Division of Hematology Malignancies
Department of Medical Oncology
Thomas Jefferson University
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Program Director Disclosure

Program Director

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Steven M. Horwitz, MD, has disclosed that he has received consultant/advisor/speaker fees from Acrotech, Affimed, Cimeio Therapeutics, Daiichi Sankyo, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, ONO Pharmaceuticals, Secura Bio, Shoreline Biosciences, Takeda, Trillium, Tubulis, Vividion Therapeutics, and Yingli Pharma and received funds for research support from ADC Therapeutics, Affimed, C4 Therapeutics, Celgene, Crispr Therapeutics, Daiichi Sankyo, Kyowa Hakko Kirin, Millennium/Takeda, Seattle Genetics, and Verastem/ Secura Bio.

Faculty Disclosure

Primary Author

Pierluigi Porcu, MD

Professor and Director
Division of Hematology Malignancies
Department of Medical Oncology
Thomas Jefferson University
Philadelphia, Pennsylvania

Pierluigi Porcu, MD, has disclosed that he has received consultant/advisor/speaker fees from Daiichi Sankyo, Dren Bio, Innate Pharma, MorphoSys, and Viracta and has served on the data and safety monitoring board for LOXO Oncology.